Aptevo Therapeutics Announces CEO Transition: Lamothe to Lead, White to Executive Chair
APVO is trading near its 52-week low of $6.88 (5.5% above the low).
Summary
Aptevo Therapeutics announced a leadership transition, with current CEO Marvin L. White moving to Executive Chair and COO Jeff Lamothe being promoted to President and CEO, effective April 1, 2026.
Key Events · Executive and Board Changes · APVO
-
CEO Transition Announced
Marvin L. White will retire as President and Chief Executive Officer, effective April 1, 2026, and transition to the role of Executive Chair of the Board.
-
New CEO Appointed
Jeff Lamothe, currently Chief Operating Officer, will assume the role of President and Chief Executive Officer and join the Board of Directors, effective April 1, 2026.
-
Board Leadership Change
John E. Niederhuber, M.D., will transition from Chairman of the Board to Lead Independent Director, effective April 1, 2026.
-
Executive Compensation Details
New CEO Jeff Lamothe will receive an annual base salary of $650,000, an annual bonus target of 60% of his base salary, and a one-time promotional award of $150,000. Marvin White's annual base salary as Executive Chair will be $275,000 with no bonus eligibility.
Analysis · APVO · Life Sciences
This filing details a significant leadership transition at Aptevo Therapeutics, with current CEO Marvin L. White moving to Executive Chair and COO Jeff Lamothe stepping into the CEO role. For a clinical-stage biotechnology company, especially one with a small market capitalization and recent substantial financing activities, leadership stability and strategic direction are critical. The internal promotion of Mr. Lamothe, who has a long history with the company, and Mr. White's continued involvement as Executive Chair, suggest a planned and orderly transition aimed at maintaining continuity and focusing on long-term growth. This move provides clarity on the company's future leadership as it navigates clinical development and capital deployment.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1939 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $7.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $6.88 to $1,616.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.